Related Experiment Video

Updated: Sep 28, 2025

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
11:10

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation

Published on: July 6, 2022

2.4K

Targeted therapy of cognitive deficits in fragile X syndrome

A Puścian1,2,3, M Winiarski4, J Borowska4

  • 1Nencki Institute of Experimental Biology of Polish Academy of Sciences, Warsaw, Poland. a.puscian@nencki.edu.pl.

Molecular Psychiatry
|March 31, 2022
PubMed

Insights

Targeted nanoparticles delivering TIMP-1 to the amygdala rescued cognitive deficits in a mouse model of Fragile X syndrome (FXS). This symptom-specific approach restored synaptic plasticity, offering a novel therapeutic strategy for FXS-related cognitive impairment.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Neuropsychiatric disorders require new therapeutic strategies targeting individual symptoms.
  • Fragile X syndrome (FXS), a leading genetic cause of intellectual disability and autism, presents significant treatment challenges.
  • Current research focuses on understanding FXS mechanisms to develop targeted therapies.

Purpose of the Study:

  • To investigate a symptom- and circuit-specific approach for rescuing reward learning deficits in a mouse model of FXS.
  • To evaluate the efficacy of designer nanoparticles loaded with TIMP metalloproteinase inhibitor 1 (TIMP-1) for treating cognitive impairments in FXS.
  • To explore the impact of this therapeutic strategy on neuronal plasticity and synaptic structure.

Main Methods:

  • Utilized high-throughput, automated behavioral tests to assess cognition and social behavior in Fmr1 knockout mice.
  • Administered circuit-targeted injections of designer nanoparticles carrying TIMP-1 into the central amygdala.
  • Performed electrophysiological recordings (long-term potentiation) and high-resolution electron microscopy to analyze synaptic plasticity and neuronal ultrastructure.

Main Results:

  • Central amygdala-targeted delivery of TIMP-1 nanoparticles successfully reversed impaired cognition in Fmr1 knockout mice.
  • The treatment demonstrated symptom specificity, showing no effect on social behavior deficits.
  • Restored functional synaptic plasticity and improved neuronal ultrastructure in the central amygdala were observed.

Conclusions:

  • A targeted, symptom-specific therapeutic strategy using TIMP-1 nanoparticles can effectively remedy cognitive deficits in Fragile X syndrome.
  • This approach highlights the potential of mechanism-based interventions tailored to specific symptoms and neural circuits.
  • The findings provide a foundation for developing novel treatments for cognitive impairments associated with FXS and potentially other neuropsychiatric disorders.

More Related Videos

TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism10:58

TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism

Published on: December 28, 2010

17.1K
A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

8.0K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
274
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
219
Cognitive Therapy01:25

Cognitive Therapy

Cognitive therapy, pioneered by Aaron T. Beck in the 1960s, is a structured approach to addressing psychological distress by focusing on the influence of thoughts on emotions and behaviors. All cognitive therapies involve the basic assumption that human beings have control over their feelings, and that how individuals feel about something depends on how they think about it. Unlike psychoanalytic methods that delve into unconscious processes or humanistic approaches emphasizing...
477
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K